Rhythm Pharmaceuticals Inc
NASDAQ:RYTM

Watchlist Manager
Rhythm Pharmaceuticals Inc Logo
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Watchlist
Price: 56.12 USD 1.15% Market Closed
Market Cap: 3.4B USD
Have any thoughts about
Rhythm Pharmaceuticals Inc?
Write Note

Rhythm Pharmaceuticals Inc
Interest Income Expense

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Rhythm Pharmaceuticals Inc
Interest Income Expense Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Interest Income Expense CAGR 3Y CAGR 5Y CAGR 10Y
Rhythm Pharmaceuticals Inc
NASDAQ:RYTM
Interest Income Expense
$4.8m
CAGR 3-Years
113%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Interest Income Expense
-$2B
CAGR 3-Years
7%
CAGR 5-Years
-9%
CAGR 10-Years
-13%
Gilead Sciences Inc
NASDAQ:GILD
Interest Income Expense
-$948m
CAGR 3-Years
26%
CAGR 5-Years
-6%
CAGR 10-Years
-10%
Amgen Inc
NASDAQ:AMGN
Interest Income Expense
-$2.4B
CAGR 3-Years
-34%
CAGR 5-Years
-29%
CAGR 10-Years
-15%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Interest Income Expense
$598m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Interest Income Expense
$990m
CAGR 3-Years
23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Rhythm Pharmaceuticals Inc
Glance View

Market Cap
3.4B USD
Industry
Biotechnology

Rhythm Pharmaceuticals Inc. emerged with a resolute focus, aiming to transform the landscape for individuals grappling with rare genetic disorders of obesity. Founded on the premise that certain predispositions to obesity are deeply rooted in genetics, Rhythm embarked on a journey to develop treatments that target the melanocortin-4 receptor (MC4R) pathway. This pathway plays a critical role in regulating hunger, energy expenditure, and overall body weight. Their flagship product, Imcivree (setmelanotide), gained approval and marked a significant stride forward for the company. It is specifically designed to address the underlying genetic causes of obesity, offering hope to patients who previously had limited therapeutic options. The business model of Rhythm Pharmaceuticals is patient-centric, grounded in innovation and strategic collaborations. They generate revenue through the commercialization of Imcivree, facilitated by partnerships with healthcare providers and institutions that benefit from the specialized treatment they offer. Additionally, Rhythm actively invests in research and development, continually seeking to expand the applicability of their products to other genetic obesity-related conditions. By maintaining a robust pipeline and leveraging scientific advancements, the company positions itself as a pioneer in addressing an underserved niche, sustainably growing through targeted drug development and market expansion initiatives.

RYTM Intrinsic Value
43.71 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Rhythm Pharmaceuticals Inc's Interest Income Expense?
Interest Income Expense
4.8m USD

Based on the financial report for Sep 30, 2024, Rhythm Pharmaceuticals Inc's Interest Income Expense amounts to 4.8m USD.

What is Rhythm Pharmaceuticals Inc's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
-3%

Over the last year, the Interest Income Expense growth was 633%. The average annual Interest Income Expense growth rates for Rhythm Pharmaceuticals Inc have been 113% over the past three years , -3% over the past five years .

Back to Top